DRF-1042
Product Sizes
100 mg
£ POA
HY-125331-100MG
5 mg
£ POA
HY-125331-5MG
10 mg
£ POA
HY-125331-10MG
50 mg
£ POA
HY-125331-50MG
25 mg
£ POA
HY-125331-25MG
About this Product
- SKU:
- HY-125331
- Application:
- Antibody Microarray
- CAS Number:
- 200619-13-2
- Extra Details:
- DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype[1][2].
- Molecular Weight:
- 408.40
- Purity:
- 98.06
- References:
- [1]Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.|[2]Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.
- Research Area:
- Cancer
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- -20[o]C (Powder; stored under nitrogen)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Conjugated Protein
- Pathway:
- Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage
